Introduction:
Swiss contract drug manufacturer Lonza Group Ltd. has partnered with Oxford Nanopore Technologies plc. to develop and market a test that can assess the quality attributes of mRNA products. This collaboration aims to enhance the analysis of mRNA products, which play a crucial role in the prevention and treatment of various diseases.
- Lonza Group Ltd. and Oxford Nanopore Technologies plc. are collaborating to develop a test that can assess the quality attributes of mRNA products.
- The test will involve directly sequencing the DNA template and messenger RNA (mRNA) using Oxford Nanopore’s technology.
- By incorporating nanopore-based sequencing into the manufacturing process, the test aims to reduce analytical testing time and improve the development of mRNA therapeutics.
- Oxford Nanopore will transfer workflows to Lonza for validation, and Lonza plans to incorporate the sequencing technology into its analytical development workflow offerings.
- This collaboration has the potential to simplify the regulatory review process and accelerate the development of mRNA therapeutics.
Conclusion:
The collaboration between Lonza Group Ltd. and Oxford Nanopore Technologies plc. aims to enhance the analysis of mRNA products by developing a test that can assess their quality attributes. By directly sequencing the DNA template and mRNA, this test has the potential to reduce analytical testing time and improve the development of mRNA therapeutics. The partnership between these two companies can contribute to the advancement of mRNA technology in the prevention and treatment of various diseases.
